RT Journal Article
T1 Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients.
A1 Vazquez-Bourgon, Javier
A1 Ortiz-Garcia de la Foz, Victor
A1 Suarez-Pereira, Irene
A1 Iruzubieta, Paula
A1 Arias-Loste, Maria Teresa
A1 Setien-Suero, Esther
A1 Ayesa-Arriola, Rosa
A1 Gomez-Revuelta, Marcos
A1 Crespo, Javier
A1 Crespo Facorro, Benedicto
K1 Antipsychotic treatment
K1 Cannabis
K1 First-episode psychosis
K1 Liver fibrosis
K1 Liver steatosis
K1 Medication naïve
K1 Tolerability
K1 Treatment outcome
AB Increased incidence of obesity and excess weight lead to an increased incidence of non-alcoholic fatty liver disease (NAFLD). Recent evidence indicates a protective effect of cannabis consumption on weight gain and related metabolic alterations in psychosis patients. Overall, patients are at greater risk of presenting fatty diseases, such as NAFLD, partly due to lipid and glycemic metabolic disturbances. However, there are no previous studies on the likely effect of cannabis on liver steatosis. We aimed to explore if cannabis consumption had an effect on hepatic steatosis, in a sample of first-episode (FEP) non-affective psychosis. A total of 390 patients were evaluated at baseline and after 3 years of initiating the antipsychotic treatment. Anthropometric measurements and liver, lipid, and glycemic parameters were obtained at both time points. All but 6.7% of patients were drug-naïve at entry, and they self-reported their cannabis use at both time points. Liver steatosis and fibrosis were evaluated through validated clinical scores (Fatty Liver Index [FLI], Fibrosis-4 [FIB-4], and NAFLD). At 3-year follow-up, cannabis users presented significantly lower FLI scores than non-users (F = 13.874; p  Cannabis consumption may produce a protective effect against liver steatosis in psychosis, probably through the modulation of antipsychotic-induced weight gain.
PB Elsevier
YR 2019
FD 2019-06-20
LK http://hdl.handle.net/10668/14157
UL http://hdl.handle.net/10668/14157
LA en
NO Vázquez-Bourgon J, Ortiz-García de la Foz V, Suarez-Pereira I, Iruzubieta P, Arias-Loste MT, Setién-Suero E, et al. Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109677
DS RISalud
RD Apr 10, 2025